Lipid-altering therapy and Atrial fibrillation

Justin M. Bachmann, Maulik Majmudar, Christine Tompkins, Roger S. Blumenthal, Joseph E. Marine

Research output: Contribution to journalReview articlepeer-review


Atrial fibrillation (AF) is a common cardiac arrhythmia with significant morbidity and public health cost. Because of limitations of efficacy and safety of conventional antiarrhythmic agents, alternative therapies for AF are needed. The potential antiarrhythmic properties of lipid-altering therapy, including the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and fish oils, are increasingly recognized, particularly in light of their potential anti-inflammatory properties. This review examines the known effects of lipid-altering therapy on atrial arrhythmias in both experimental and clinical settings. Inflammatory states, such as postcardiac surgery and AF of recent onset, show promise as targets. In contrast, lipid-lowering therapy is less likely to affect longstanding persistent AF. Current recommendations for the use of lipid-altering therapy for prevention and treatment of AF are summarized.

Original languageEnglish (US)
Pages (from-to)197-204
Number of pages8
JournalCardiology in Review
Issue number4
StatePublished - Jul 2008

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Lipid-altering therapy and Atrial fibrillation'. Together they form a unique fingerprint.

Cite this